Warfarin Monitoring in Antiphospholipid Syndrome and Lupus Anticoagulant

Annals of Pharmacotherapy

Volumn 48, Issue 11, 2014, Pages 1479-1483

  Crowl, Ashley ^a,b   Schullo Feulner, Anne ^b,c   Moon, Jean Y ^b,d  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

antiphospholipid syndrome; CFX; INR; lupus anticoagulant; monitoring

Indexed keywords

BLOOD CLOTTING FACTOR; CHROMOGENIC FACTOR X; LUPUS ANTICOAGULANT; REAGENT; THROMBOPLASTIN; UNCLASSIFIED DRUG; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; CHROMOGENIC SUBSTRATE;

ACCURACY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; DRUG MONITORING; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT MONITORING; RELIABILITY; REVIEW; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; IMMUNOLOGY; PROCEDURES;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CHROMOGENIC COMPOUNDS; DRUG MONITORING; FACTOR X; HUMANS; INTERNATIONAL NORMALIZED RATIO; LUPUS COAGULATION INHIBITOR; WARFARIN;

EID: 84908096712     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014546361     Document Type: Review

References (20)

1. Moll S,Ortel T.Monitoring warfarin therapy in patients with lupus anticoagulants.Ann Intern Med. 1997;127:177-185
2. Robert A,Querrec A,Le, Delahousse B,.Control of oral anticoagulation in patients with the antiphospholipid syndrome: influence of the lupus anticoagulant on international normalized ratio.Thromb Haemost. 1998;80:99-103
3. Holbrook A,Schulman S,Witt D,.Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012;141:e152S-e184S
4. Balaban M,Stanrić V,Rincić G,.Recurrent venous thrombosis despite “optimal anticoagulation therapy” for antiphospholipid syndrome: could new oral anticoagulants solve the problem?.Acta Clin Croat. 2010;49:469-477
5. Rosborough T,Shepherd M.Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant.Pharmacotherapy. 2004;24:838-842
6. Sanfelippo M,Sennet J,McMahon E.Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant.WMJ. 2000;99 (3): 62-64
7. Tripodi A,Chantarangkul V,Clerici M,Negri B,Galli M,Mannucci P.Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant: results of a collaborative study involving nine commercial thromboplastins.Br J Haematol. 2001;115:672-678
8. Lawrie A,Purdy G,Mackie I,Machin S.Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome.Br J Haematol. 1997;98:887-892
9. McGlasson D,Romick B,Rubal B.Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy.Blood Coagul Fibrinolysis. 2008;19:513-517
10. Willis R,Harris E,Pierangeli S.Pathogenesis of the antiphospholipid syndrome.Semin Thromb Hemost. 2012;38:305-321
11. Galli M.The antiphospholipid triangle.J Thromb Haemost. 2010;8:234-236
12. Cohen D,Berger S,Steup-Beekman G,Bloemenkamp K,Bajema I.Diagnosis and management of the antiphospholipid syndrome.BMJ. 2010;340:c2541
13. Cervera R,Piette J,Font J,.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.Arthritis Rheum. 2002;46:1019-1027
14. Crowther M,Ginsberg J,Julian J,.A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.N Engl J Med. 2003;349:1133-1138
15. Adcock D,Duff S.Enhanced standardization of the international normalized ratio through the use of plasma calibrants: a concise review.Blood Coagul Fibrinolysis. 2000;11:583-590
16. Rosborough TK,Jacobsen JM,Shepherd MF.Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients.Blood Coagul Fibrinolysis. 2010;21:242-244
17. ANIARA. BIOPHEN factor X (Chromogenic). http://www.aniara.com/PROD/A221705.html. Accessed January 3, 2013.
18. Rosove M,Brewer P.Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.Ann Intern Med. 1992;117:303-308
19. Khamashta M,Cuadrado M,Mujic F,Taub N,Hunt B,Hughes G.The management of thrombosis in the antiphospholipid-antibody syndrome.N Engl J Med. 1995;332:993-997
20. Krnic-Barrie S,O’Connor C,Looney S,Pierangeli S,Harris E.A retrospective review of 61 patients with anti-phospholipid syndrome: analysis of factors influencing recurrent thrombosis.Arch Intern Med. 1997;157:2101-2108